Loading...
XNAS
PAHC
Market cap1.31bUSD
Jul 09, Last price  
32.38USD
1D
-0.18%
1Q
-44.07%
Jan 2017
10.51%
IPO
94.24%
Name

PHIBRO ANIMAL HEALTH CORP

Chart & Performance

D1W1MN
XNAS:PAHC chart
P/E
27.20
P/S
1.01
EPS
1.19
Div Yield, %
1.48%
Shrs. gr., 5y
0.10%
Rev. gr., 5y
10.12%
Revenues
1.30b
+27.37%
398,400,000453,000,000511,400,000537,100,000594,200,000618,333,000654,101,000653,151,000691,900,000748,591,000751,500,000764,300,000820,000,000828,000,000800,354,000833,350,000942,261,000977,889,0001,017,679,0001,296,215,000
Net income
48m
+1,897.68%
-13,100,000-6,700,0002,200,000-8,300,00042,100,000-12,922,0006,976,00024,891,000-3,100,00060,280,00082,700,00064,600,00064,900,00054,700,00033,552,00054,385,00049,175,00032,606,0002,416,00048,264,000
CFO
80m
-8.53%
34,660,0002,860,000-6,160,000810,000-4,730,000-4,680,00031,988,000415,000-712,00068,704,00037,218,00098,400,00070,008,00047,169,00059,348,00048,306,00031,649,00013,310,00087,594,00080,124,000
Dividend
Nov 26, 20250.12 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
IPO date
Apr 11, 2014
Employees
1,920
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT